麦澜德(688273) - 投资者关系活动记录表（2024年9月5日）

Financial Performance - The company achieved operating revenue of 228 million CNY in the first half of 2024, representing a year-on-year increase of 11.73% [1] - The net profit attributable to shareholders reached 72.61 million CNY, up 23.39% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 66.06 million CNY, reflecting a growth of 32.81% [2] - R&D investment amounted to 26.42 million CNY, accounting for 11.57% of the operating revenue [2] - As of June 30, 2024, total assets were 1.539 billion CNY, with net assets attributable to shareholders at 1.345 billion CNY [2] Market Trends and Product Development - The company is focusing on pelvic floor and gynecological rehabilitation products, with the "Magnetoelectric Thermal Imaging · Smart Integration PI-ONE" system launched in March 2024 [2] - There is a growing demand for pelvic floor dysfunction (PFD) treatment, with increasing awareness and screening in primary healthcare settings [3] - The company is expanding its marketing strategy to reach secondary and primary hospitals, community health institutions, and clinics to enhance PFD screening [3] Strategic Planning - The company plans to adopt a dual strategy of "independent R&D + external expansion" to enhance its reproductive health and anti-aging product lines [4] - The sales model is primarily distribution-based, with direct sales supplementing in non-medical markets [5] - Future development in the sports rehabilitation sector will be approached with caution, observing market opportunities before significant investment [5] Risk Management - The company emphasizes that any forecasts regarding industry trends or strategic plans should not be interpreted as commitments or guarantees of performance [5]